Weiland O - Search Results

1

Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort.

Welzel TM, Petersen J, Herzer K, Ferenci P, Gschwantler M, Wedemeyer H, Berg T, Spengler U, Weiland O, van der Valk M, Rockstroh J, Peck-Radosavljevic M, Zhao Y, Jimenez-Exposito MJ, Zeuzem S. Welzel TM, et al. Among authors: weiland o. Gut. 2016 Nov;65(11):1861-1870. doi: 10.1136/gutjnl-2016-312444. Epub 2016 Sep 7. Gut. 2016. PMID: 27605539 Free PMC article.

2

Combined treatment with interferon alpha-2b and ribavirin for chronic hepatitis C in patients with a previous non-response or non-sustained response to interferon alone.

Schvarcz R, Yun ZB, Sönnerborg A, Weiland O. Schvarcz R, et al. Among authors: weiland o. J Med Virol. 1995 May;46(1):43-7. doi: 10.1002/jmv.1890460110. J Med Virol. 1995. PMID: 7623006 Clinical Trial.

3

Interferon therapy in chronic hepatitis C virus infection.

Weiland O. Weiland O. FEMS Microbiol Rev. 1994 Jul;14(3):279-88. doi: 10.1111/j.1574-6976.1994.tb00100.x. FEMS Microbiol Rev. 1994. PMID: 8086199 Review.

4

Combination treatment with interferon alfa-2b and ribavirin for chronic hepatitis C in patients who have failed to achieve sustained response to interferon alone: Swedish experience.

Schvarcz R, Ando Y, Sönnerborg A, Weiland O. Schvarcz R, et al. Among authors: weiland o. J Hepatol. 1995;23 Suppl 2:17-21. J Hepatol. 1995. PMID: 8720289 Clinical Trial.

5

Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group.

Reichard O, Norkrans G, Frydén A, Braconier JH, Sönnerborg A, Weiland O. Reichard O, et al. Among authors: weiland o. Lancet. 1998 Jan 10;351(9096):83-7. doi: 10.1016/s0140-6736(97)06088-1. Lancet. 1998. PMID: 9439491 Clinical Trial.

6

Can HCV infection be cleared?

Weiland O. Weiland O. Lancet. 1998 Aug 29;352(9129):669-70. doi: 10.1016/s0140-6736(05)60815-x. Lancet. 1998. PMID: 9728977 No abstract available.

7

Histological and virological long-term outcome in patients treated with interferon-alpha2b and ribavirin for chronic hepatitis C.

Schvarcz R, Glaumann H, Reichard O, Weiland O. Schvarcz R, et al. Among authors: weiland o. J Viral Hepat. 1999 May;6(3):237-42. doi: 10.1046/j.1365-2893.1999.00156.x. J Viral Hepat. 1999. PMID: 10607236 Clinical Trial.

8

Interferon and ribavirin combination therapy: indications and schedules.

Weiland O. Weiland O. Forum (Genova). 2000 Jan-Mar;10(1):22-8. Forum (Genova). 2000. PMID: 10717255 Review.

9

Viral kinetics and treatment response in patients with hepatitis C during induction and standard interferon therapy in combination with ribavirin.

Carlsson T, Weiland O, Reichard O. Carlsson T, et al. Among authors: weiland o. Scand J Gastroenterol. 2002 Oct;37(10):1228-34. doi: 10.1080/003655202760373461. Scand J Gastroenterol. 2002. PMID: 12408530 Clinical Trial.

10

Long term clinical outcome of chronic hepatitis C patients with sustained virological response to interferon monotherapy.

Veldt BJ, Saracco G, Boyer N, Cammà C, Bellobuono A, Hopf U, Castillo I, Weiland O, Nevens F, Hansen BE, Schalm SW. Veldt BJ, et al. Among authors: weiland o. Gut. 2004 Oct;53(10):1504-8. doi: 10.1136/gut.2003.038257. Gut. 2004. PMID: 15361504 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

263 results

Search Page

Filters